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Fractionated Illumination Significantly Improves
the Response of Superficial Basal Cell Carcinoma
to Aminolevulinic Acid Photodynamic Therapy
Ellen R.M. de Haas1, Bastiaan Kruijt2, Henricus J.C.M. Sterenborg2, H.A. Martino Neumann1
and Dominic J. Robinson1,2
Photodynamic therapy (PDT) of superficial basal cell carcinoma (sBCC) using topical 5-aminolevulinic acid (ALA)
and a light fluence of 75–100 J cm2 yields unsatisfactory long-term results. In several animal models,
illumination with two light fractions 2 hours apart was considerably more effective than single illumination.
Response is further enhanced if the fluence of the first light fraction is reduced, although the cumulative
fluence is maintained. We compared the response of sBCC to a single illumination and 2-fold illumination
scheme in which two light fractions of 20 and 80 J cm2 are performed 4 and 6 hours after the application of a
single dose of 20% ALA. We randomly assigned 154 patients with a total of 505 primary sBCC into two treatment
groups. Two hundred and forty-three lesions were treated using a single illumination of 75 J cm2 at a fluence
rate of 50 mW cm2. Fractionated PDT, at the same fluence rate, was performed on 262 lesions. The complete
response (CR) following a 2-fold illumination scheme is significantly greater than that following a single light
fraction (P¼ 0.002, log-rank test). Twelve months after therapy, CR rate to a 2-fold illumination is 97%, whereas
the CR to a single illumination is 89%.
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INTRODUCTION
Photodynamic therapy (PDT) of superficial (non-) malignant
skin lesions, using topically applied 5-aminolevulinic acid
(ALA) to endogenously generate the photosensitizer proto-
porphyrin IX (PpIX), was introduced by Kennedy et al. in 1990.
Initially, high (80–100%) complete response (CR) rates were
reported for topical ALA-mediated photodynamic therapy
(ALA-PDT) in the treatment of superficial non-melanoma skin
cancer (Kennedy et al., 1990; Kennedy and Pottier, 1992;
Svanberg et al., 1994; Meijnders et al., 1996; Wennberg et al.,
1996). However, comparing the results of ALA-PDT, a
considerable variation in CR rates is observed; long-term
response rates vary from 30 to 100% (Calzavara-Pinton, 1995).
To achieve higher CR, some investigators have treated lesions
more than once (Morton et al., 1996; Haller et al., 2000). The
success of topical ALA-PDT is dependent on several factors. In
addition to penetration of ALA into the skin(-lesion) and the
formation of a therapeutic concentration of PpIX, CR depends
significantly on tumor thickness and duration of ALA applica-
tion (Fink-Puches et al., 1998). Curettage before topical ALA-
PDT may significantly improve CR rates, in particular for
nodular basal cell carcinoma (Morton et al., 1998; Soler et al.,
1999). In an attempt to increase the effectiveness of ALA-PDT,
modified prodrugs of ALA have also been used such as a
methyl aminolevulinate (MAL) and other esters (Van den Akker
et al., 2000a, b, 2003). Although no comparative study has
been performed to compare the clinical response using ALA
and MAL, clinical studies published using MAL-PDT also show
a variation in response rate. Horn et al. (2003) reported a
recurrence rate of 18% in a study of 94 basal cell carcinomas
that were treated with MAL-PDT (two treatments a week apart,
follow-up (FU) 24 months. Soler et al. (2001) reported the
treatment of 350 curettaged nodular basal cell carcinoma and
superficial basal cell carcinoma (sBCC) using MAL-PDT in two
sessions with a CR of 79% (FU 22–24 months). The approved
scheme of MAL-PDT in Europe consists of two treatments a
week apart. Rhodes et al. (2004) performed a comparative
study using MAL-PDT versus surgery for nodular basal cell
carcinomas, achieving 10% recurrence rate in the MAL-PDT
group versus 2% recurrence rate in the surgery group.
Recently, Van Iersel et al. (2005) reported their results after
primary surgery for a basal cell carcinoma being a 5-year
cumulative risk of only 2.1%. These studies support the need
to improve the response of sBCC to both MAL and ALA-PDT.
We have performed series of pre-clinical studies investi-
gating the effects of fractionating the illumination in PDT in a
variety of model systems (Van der Veen et al., 1994, 1999;
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De Bruijn et al., 1999; Robinson et al., 2000, 2003; Thissen
et al., 2002). We have shown increased efficacy of ALA-PDT
using fractionated illumination with relatively long dark
intervals between two light fractions (Van der Veen et al.,
1994). For topical administration, we have shown that a
2-hour dark interval is necessary to achieve a significant
increase in response. We have shown that choice of fluence
(rate) for the first light fraction is critical, and that a high
fluence for the second light fraction is necessary for maximal
tissue response (Robinson et al., 2003). Our first clinical pilot
study using fractionated ALA-PDT using two equal light
fractions of 45 J cm2 with a 2-hour dark interval resulted in a
CR rate of 84% (mean FU 59 months; range 44–82 months,
n¼67) (Star et al., 2006). This was an encouraging result, but
we were unable to show a statistically significant increase in
response compared to a single illumination. This is probably
owing to the choice of a non-optimized illumination scheme
and the small number of lesions treated. Here, we report on a
randomized comparative prospective open clinical study
between a standard ALA-PDT treatment scheme using a
fluence of 75 J cm2, 4 hours after the administration of ALA
and a 2-fold illumination using 20þ 80 J cm2, delivered 4 and
6 hours after the administration of ALA. We also investigated
the kinetics of PpIX fluorescence during the 2-fold illumination
scheme and their relation to the mechanism of response.
RESULTS
A 2-fold illumination scheme of 20þ 80 J cm2 with a 2-hour
dark interval results in a significantly better clinical response to
ALA-PDT over a single light fraction
The relative CR of lesions to ALA-PDT using a single light
fraction and a 2-fold illumination scheme is shown in
Figure 1. The CR using a 2-fold illumination is significantly
greater than that following a single light fraction (P¼0.002,
log-rank test). Twelve months after therapy, the relative CR in
the 2-fold illumination group is 97%, whereas the corres-
ponding CR in the single illumination group is 89%. Of the
243 lesions in the single illumination group, 32 lesions failed
to respond or recurred during the FU period. Of these lesions,
10 lesions were retreated with ALA-PDT, with five lesions
receiving a second single illumination and five were retreated
using a 2-fold illuminated scheme; all resulted in CR
(minimum FU 12 months). These lesions were not included
as responders in our statistical analysis of CR. The remaining
22 lesions were surgically excised and consisted 17 nodular,
one micro-nodular, two morphemic, and two sBCC.
Only 10 of the 262 lesions in the 2-fold illumination group
did not show CR. Five lesions were excised and found to be
nodular (n¼ 3) or morphemic (n¼ 2) basal cell carcinomas
and five were retreated with 2-fold illumination ALA-PDT
and responded (FU 7, 8, 11, 14, and 16 months without
recurrence). These were included as non-responders,
although after a second treatment CR was seen.
A sub-group analysis in which only histologically proven
sBCCs are included shows a similar pattern of CR between
the single- and 2-fold illumination groups. Twelve months
after therapy, the relative CR in the 2-fold illumination group
is 98%, whereas the corresponding CR in the single
illumination group is 85% (P¼ 0.0003, log-rank test).
PDT was well tolerated in both illumination groups, and all
patients completed therapy
A minority of patients (14%) required pain relief in addition to
2% lidocaine already present in the ALA ointment. The
majority of patients, 133 out of 154 (86%), did not require
additional pain relief during or after the therapeutic
illumination. The details of patients who required pain
medication are shown in Table 1. A greater number of
patients required pain relief in the 2-fold illumination group
than in the single illumination group. In the single illumina-
tion group, five patients required pain relief for six of 32
treated lesions. In the 2-fold illumination group, 15 patients
required pain relief for 44 of 64 treated lesions. There was no
consistent difference in pain during each of the 2-fold light
fractions, although in general patients reported more pain
during the first illumination. Pain resolved quickly during the
dark interval. Our pre-clinical animal data suggested that the
acute response to therapy might be more severe in the 2-fold
illumination group. In the 2-fold illumination, crusts formed
following therapy in 15 lesions in six patients. In the single
illumination group, crusts were seen in two lesions in two
patients. Despite crust formation, cosmetic outcome was
good in all lesions. The relationship between acute response
and the need for pain relief is shown in Table 1. One patient
showed a pustular skin reaction in 11 of 16 lesions, which
lasted 5 days. This was cultured and proven to be non-
bacterial. A small number (19) showed persistent hypopig-
mentation at the illumination site 1 year after therapy.
There was no significant difference in response rates for
the different light sources used. The response rate following a
2-fold illumination scheme was greater for each light source.
We found no statistically significant difference between the
response rates for the different light sources within each
illumination group. A comparison of the response of lesions
to a single- and a 2-fold illumination scheme for each
individual light source is shown in Table 2.
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Figure 1. A 2-fold illumination scheme of 20þ 80 J cm2 with a 2-hour dark
interval results in a significantly better clinical response to ALA-PDT.
Kaplan–Meier curves for disease-free rates for relative CR of sBCC using a
single light fraction of 75 J cm2, 4 hours after the application of ALA (— - - -
— - -) and a 2-fold illumination scheme of 20þ 80 J cm2 4 and 6 hours after
the application of ALA. (———). Statistical significance is tested for 1-year FU
(P¼0.002, log-rank test: relative risk 0.3: confidence interval 0.15–0.59).
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The kinetics of PpIX fluorescence were in accordance with
that found in pre-clinical animal models. Figure 2 shows the
mean fluorescence intensity present before and after the first
light fraction of 20 J cm2 and 2 hours later, immediately
before the second light fraction. The PpIX fluorescence before
the first light fraction varied considerably, between the
lesions of each patient as well as between patients. When
the fluorescence of all lesions is normalized to 100%, the
mean fluorescence after the illumination is 47% and rises to
69% before the second illumination. There was considerable
variation in PpIX fluorescence between lesions and between
patients. Likewise, photobleaching varied widely, despite
fixed illumination parameters. The average extent of photo-
bleaching of 47% during the first light fraction is similar to
that we have found in our pre-clinical studies. The amount
of re-synthesis during the dark interval and the total amount
of PpIX utilized in a single illumination compared to that in a
2-fold illumination scheme is also consistent to that we have
seen in our pre-clinical studies (Robinson et al., 2003).
DISCUSSION
We have demonstrated that a statistically significant improve-
ment in CR rate can be achieved using a light fractionation
scheme with a 2-hour dark interval between light fractions of
Table 1. Acute response and medication administered to patients who required pain relief and acute response
(cosmetic outcome in these lesions was determined as good in all cases)
75 J cm2 20+80 J cm2
Patient
Lesions requiring
medication
(illuminated lesions) Location Anesthesia
Lesions requiring
medication
(illuminated lesions) Location Anesthesia
Timing, acute response,
and other remarks
A 0 (6) 4 (7) Trunk Paracetamol After first fraction,
crusts+ (20+80 J cm2)
B 1 (1) Vertex Paracetamol After illumination
C 0 (4) 2 face,
2 trunk
2 (2) Face Paracetamol After first fraction
D 0 (5) Arm 2 (2) Arm, face Paracetamol After first fraction
E 0 (2) Trunk 7 (7) 3 arm, 3 trunk,
1 leg
Paracetamol After first fraction
F 0 (15) 2 face, 10
trunk, 3 arm
3 (19) 13 trunk,
6 arm
Paracetamol In advance of three
lesions treated
at the end of the
treatment day
G 1 (1) Face Paracetamol 0 (1) Face After illumination
H 2 (2) Face Paracetamol After second fraction
I 4 (4) Leg Paracetamol After first fraction crusts+
J 4 (4) 2 trunk, 2 leg Paracetamol After first fraction (2)
in advance (2)
K 1 (1) Face Lidocaine Before second fraction
L 1 (1) Face Lidocaine Before second fraction
M 4 (4) 1 face, 2 arm,
1 trunk
Lidocaine Before second fraction,
rheumatic patient
N 1 (1) Arm Lidocaine During illumination, crusts+
O 2 (2) Trunk Lidocaine Before second fraction
P 2 (2) Face Lidocaine During illumination
Q 1 (1) Vertex Bupivacaine Block before first fraction
R 4 (4) face Bupivacaine Block before first fraction
and local during first fraction
S 1 (1) Face Bupivacaine During illumination, crusts+
T 1 (1) Vertex Bupivacaine Block before first fraction,
painful
second fraction, crusts+
U 2 (2) Arm Bupivacaine During first illumination
21 6 (32) 5 44 (64) 15
Bold values signify total.
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20 and 80 J cm2 compared to a single light fraction (97
versus 89% CR, 12 months FU, P¼0.002, log-rank test).
The lower response rate found with a single light fraction
(89%) is similar to our previous results (Meijnders et al.,
1996) and is consistent with the other investigators who have
performed ALA-PDT in a single treatment session. Our choice
of 2-fold illumination scheme is based on data from a range
of pre-clinical animal studies that showed that following light
illumination, tissues continue to synthesize PpIX. Apparently,
the heme synthesis cycle is still (partly) intact and there is still
ALA available to be converted into PpIX. PpIX fluorescence
has been observed after PDT with both systemic ALA and
topical ALA (Van der Veen et al., 1994, 1999; Orenstein
et al., 1997; De Bruijn et al., 1999; af Klinteberg et al., 1999;
Robinson et al., 2000). However, these pre-clinical studies
also demonstrate the complexity of the response of tissues to
ALA-PDT and highlight the challenge for optimization
(Robinson et al., 2003). It is not simply a matter of performing
a second illumination at some arbitrary time point after a
standard single illumination. The time interval between light
fractions is a very important consideration. A 2-hour time
interval is necessary to yield a significant increase in
response. Also, the fluence delivered in the first light
fraction has a dramatic impact on the response to a 2-fold
illumination. Although the response to a light fractionation
scheme of 50þ50 J cm2 with a 2-hour dark interval is
greater than a single illumination of 100 J cm2, the increase
is not statistically significant. Reducing the fluence of the first
light fraction to 5 J cm2 and delivering a large fluence in
the second (95 J cm2) significantly increases the effective-
ness of PDT. In fact, this represents the most effective
illumination scheme that we have yet devised. A similar
pattern of response to light fractionation seems evident in
clinical ALA-PDT of sBCC. In a clinical pilot study treating
sBCC with two equal light fractions of 45þ 45 J cm2,
separated by a 2-hour dark interval, we have shown an
increase in long-term CR over that reported by other
investigators (Star et al., 2006). We were, however, not able
to show a statistically significant improvement in CR at 12
months over a single illumination of 75 J cm2. This study
shows that reducing the fluence of the first light fraction to
20 J cm2 and maintaining that of the second light fraction to
deliver a cumulative fluence of 100 J cm2 results in a
significant improvement in CR rate, just as predicted by our
pre-clinical animal studies. We note that one other factor
influenced the design of the clinical illumination scheme.
sBCCs are in general more pigmented and significantly
thicker than normal mouse epidermis. A higher light fluence
of 20 J cm2 was used, instead of the 5 J cm2 that found to
be optimal in our animal study, to ensure the deposition of
sufficient fluence at the base of each lesion.
The cumulative fluence in each of the illumination groups
is not equal. A fluence of 75 J cm2 was delivered in a single
light fraction compared to 100 J cm2 in the 2-fold illumina-
tion scheme. This is a direct consequence of our intention
to deliver a large fluence in the second light fraction
(Robinson et al., 2003). The influence of this additional
cumulative fluence on the clinical response we observe is an
important issue. A number of pre-clinical studies have
shown that photobleaching of the PpIX limits the PDT dose
that can be delivered in a single light fraction at fixed
fluence rate (Robinson et al., 1998). We have shown in
normal mouse skin that 100 J cm2 does not result in
significantly more damage than 50 J cm2. The relationship
between response to ALA-PDT and fluence has not
been systematically investigated in the clinic. Only Oseroff
(1998) has emphasized the importance of light fluence in
the treatment of sBCC by topical ALA-PDT, and this regards
the delivered of very high light fluences at high fluence rate.
He reported that a CR rate of 95% after 200 J cm2 (at a
fluence rate of 150 mW cm2) fell to 70% after 150 J cm2.
Most other investigators have applied both lower light
fluence (rate) and cumulative fluences both below 75 J cm2
and above 100 J cm2, with little evidence for a correlation
between fluence and response.
Large variations occur in our fluorescence data. Several
factors may be involved here, such as variations in tissue
optical properties, in oxygenation, and in heterogenity of
the PpIX distribution in the lesions (Martin et al., 1995). The
variations in ALA-induced sBCC fluorescence reported by
Table 2. CR of lesions treated with each light source in
each illumination group
75 J cm2 20+80 J cm2
Light source n CR (%) n CR (%) P-value
Diode laser (630 nm) 160 91 42 98 0.236
LED Omnilux (633 nm) 21 85 152 97 0.347
Broadband Red Source
Medeikonos (590–650 nm)
62 89 68 97 0.093
Total 243 89 262 97 0.002
CR, complete response; LED, light-emitting diode.
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Figure 2. Kinetics of PpIX fluorescence. The kinetics of PpIX fluorescence
were in accordance to that found in pre-clinical animal models, but did not
explain the increase in response using a 2-fold illumination scheme. The
kinetics of PpIX fluorescence intensity in sBCC during ALA-PDT with a (&)
2-fold illumination scheme and (’) the relative PpIX photobleaching during
therapy with 20 J cm2 and the re-synthesis during the dark interval between
light fractions (n¼ 17 lesions).
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af Klinteberg et al. (1999) seem somewhat less, but these
authors only report standard errors. Golub et al. (1999) also
measured large variations in ALA-induced fluorescence on
normal human skin and psoriasis and actinic keratosis
lesions. Such variability is widely observed in ALA-induced
fluorescence of normal human skin and skin lesions (Barr
et al., 1987; Marchesini et al., 1994; Star, 1995, 2006).
Accepting the large variations that seem to be a feature of
clinical fluorescence measurements, we do see a similar
trend in the kinetics of PpIX fluorescence after illumina-
tion with 20 J cm2. Importantly, we note that the original
rationale for performing a 2-fold illumination scheme was
to utilize additional PpIX that continued to be synthesized
after PDT with a single light fraction. Our recent clinical
data (Star et al., 2006) and pre-clinical data (Robinson
et al., 2003) do not support the hypothesis that significantly
more PpIX is utilized in the 2-fold illumination scheme, as
50þ50 and 5þ 95 J cm2 result in approximately the same
amount of cumulative PpIX photobleaching (P¼0.12,
Student’s t-test).
The spectral output of the light sources used in this study
may have influenced the response to a 2-fold illumination
scheme. Our pre-clinical studies have shown that the
response of tissues to PDT using the 2-fold illumination
scheme is quite sensitive to the small differences in fluence
and fluence rate of the first light fraction. Some investigators
have suggested that there may be differences in response to
PDT with (a) light sources that deliver a lower effective
fluence rate by virtue of the overlap of their spectral output
with the absorption spectrum of PpIX (Clark et al., 2003) and
(b) light sources that additionally excite the fluorescent
photoproducts of PpIX (Gudgin Dickson and Pottier, 1995).
The fact that we did not see differences in response between
light sources suggests that these effects are small and do not
impact significantly on the effective dose of the first light
fraction. This means that the current fluence and dark interval
findings in the current study are also applicable for the large
proportion of investigators that use commercially available
non-laser light sources. Our data stratified by light source
(Table 2) show that there is approximately the same increase
in response of all the light sources investigated. We expect
that statistical significance would be achieved if larger
numbers of lesions were investigated.
During the whole FU period, a significantly greater
number of recurrent or non-responding lesions were ob-
served in the single illumination group; 32/243 (13%)
compared to the 2-fold illumination group 10/262 (4%)
(P¼0.0002, Fisher’s exact test). Of the 32 lesions that did not
show CR in the single illumination group, 20 were found not
to be sBCC: nodular (18); micro-nodular (1); and morphemic
(2) at recurrence. Of the 10 lesions that did not show CR in
the 2-fold illumination group, five were found not to be sBCC
at recurrence, but nodular (3) and morphemic (2). The
presence of nodular lesions in these data was not unexpected
as diagnosis was based on clinical appearance for a significant
proportion of lesions. Fifty-four percent and 49% of lesions
were diagnosed clinically in the single- and 2-fold illumination
group, respectively. Clinical diagnostic accuracy in a derma-
tology university faculty has been shown to be approximately
70% for BCC (Presser and Taylor, 1987). If a similar accuracy
were assumed in this study, we would expect to see 38 and 35
nodular lesions in our single- and 2-fold illumination groups,
respectively. Three recurrent or non-responding nodular BCC’s
in the 2-fold illumination group represents a significantly lower
number than expected (P¼ 0.0003, Fisher’s exact test).
Although it was not out primary intention to treat nodular
lesions, we have previously shown that the 2-fold illumination
leads to deeper histological damage in pre-clinical models (De
Bruijn et al., 1999; Robinson et al., 2003). Determining the
maximum depth of BCC that can be treated with ALA-PDT is
clearly an area for future study.
The increased severity of the acute response following
therapy shows a similar pattern to the increase in damage
induced in our pre-clinical animal studies. This and the fact
that we see an accompanying increase in CR after 12 months
FU provides encouraging evidence for the value of PDT
optimization in pre-clinical animal studies. In our animal
studies, the increase in the effectiveness of the 2-fold
illumination scheme leads to scarring in some cases.
Although the clinical acute response is greater than a single
illumination, the cosmetic outcome remains good in 90% of
the lesions. We are also encouraged by the fact that patients
did not experience significantly more pain during the 2-fold
illumination scheme.
A central aim of the current study was to achieve an
optimal response to PDT in a single treatment session (i.e.
with a single application of ALA). We note that repeating
such an optimalized treatment regimen on subsequent
treatment days may lead to an even higher CR rate in sBCC
and/or a higher CR rate for other skin lesions. In conclusion,
we have demonstrated a significant increase in the CR rate
of sBCC to ALA-PDT using an illumination scheme in which
two light fractions of 20 and 80 J cm2 are delivered 4 and
6 hours after the application of ALA compared to a single
illumination scheme of 75 J cm2. Further FU is now
necessary to determine if this high CR rate is maintained.
We note that the value of these results may extend beyond
the skin, into other organs such as the esophagus and brain,
where ALA-PDT is under investigation as a treatment
modality (Bogaards et al., 2005; Pech et al., 2005).
MATERIALS AND METHODS
Patients
All patients were diagnosed as having an sBCC within the Erasmus
MC in Rotterdam. ALA-PDT was performed according to two
treatment protocols, described in detail below, approved by the
local ethics committee, according to the Declaration of Helsinki
Principles. All patients gave informed consent. Diagnosis was
determined histologically (4 mm punch biopsy) and clinically in
approximately equal proportions within each treatment group. Every
patient had at least one histologically diagnosed primary sBCC. Our
patient population consists of both first-line and secondary
dermatological care. All patients are adult Caucasians. We treated
100 patients who had in total 243 lesions, using a single illumination
scheme. Fifty-five patients with a total of 262 lesions were treated
using a 2-fold illumination scheme, described below. Both groups
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were in the same age range; in the group that received a single
fraction, the mean age was 57 years (minimum 32, maximum 81,
median 57), and in the 2-fold illumination group, the mean age was
56 years (minimum 31, maximum 83, median 56). Also, both
treatment groups included a similar number of higher risk patients as
shown in Table 3.
ALA application and local anesthesia
A topical ALA ointment we used was prepared by our Hospital
Pharmacy using 20% ALA (FLUKA, The Netherlands) in Instilagel
(Medeco BV, Oud Beijerland, The Netherlands). Instilagel was
used as vehicle because it contains lidocaine (2%), which is
considered a possible advantage in pain management (Ibbotson,
2002). The ointment was freshly prepared and stored in a refrigerator
and used within 3 days. Before application of ALA, crusts and
scaling were gently removed using a disposable curette. The
lesion was covered with a margin of 1 cm and dressed with a
semipermeable dressing (Tegaderm 3M, The Netherlands) and
light-protecting covering (aluminum foil). Patients were instructed
to stay out of the cold because of the negative effect of low
temperatures on ALA metabolism (Van den Akker et al., 2004). In
addition to the topical anesthetic in the ALA ointment, patients
received paracetamol, lidocaine (without epinephrine), or bupiva-
caine, if required.
Light sources and illumination scheme
Three light sources were used in this study. A 630 nm diode laser
(Carl Zeiss, Oberkochen, Germany) was used to provide 630 nm
illumination. Light was coupled into a 600 mm optical fiber and
projected onto the lesion using a combination of lenses to assure a
uniform fluence rate across the beam diameter. Two commercially
available broadband light sources were also used. The first had a
spectral output between 590 and 650 nm (Medeikonos, Gothenburg,
Sweden). The second was a light-emitting diode, light source with a
spectral output centered on 633 nm with a bandwidth of 20 nm
(Omnilux, Waldmann, Tiel, The Netherlands). All three light sources
were used to illuminate lesions with a margin of at least 5 mm at a
constant measured fluence rate of 50 mW cm2. It was necessary to
shield areas outside this margin for both broadband light sources. In
the single illumination group, lesions were illuminated 4 hours after
the application of ALA to a fluence of 75 J cm2. In the 2-fold
illumination group, lesions received light fractions of 20 and
80 J cm2, 4 and 6 hours after the application of ALA. ALA was
applied once. Again, both light fractions were delivered at a fluence
rate of 50 mW cm2. During the 2-h dark interval between light
fractions, lesions were covered with light-protective bandage.
Table 2 shows the number of lesions treated with each light sources
in each illumination group.
Fluorescence measurements
PpIX fluorescence measurements were acquired from a subgroup of
17 lesions in the 2-fold illumination group to investigate the kinetics
of PpIX fluorescence during therapy. In this subgroup, PDT was
performed using the diode laser. Data were acquired before ALA
application, immediately before and after the first illumination and
immediately before the second illumination. Measurements were
performed with a custom applicator attached to a fluorescence-
imaging camera (TRICAM, Storz, Tuttlingen, Germany). A uniform
excitation light field (400–450 nm) was obtained from a ring of
filtered blue light-emitting diodes mounted around the camera.
Fluorescence emission from PpIX was collected over a period of
0.25 seconds. Scattered excitation light was blocked using a long-
pass filter (Schott KV 500). Fluorescence emission from PpIX
(600–710 nm) was collected over a period of 0.25 seconds. Images
acquired at different time points are registered under translation and
rotation using landmarks in the skin surrounding the lesion (e.g. hair
follicles). Typically, a rectangular area of 4 6 cm is imaged. Within
this area, a circular region of interest approximately 0.25 cm in
diameter is defined and the average pixel intensity was used as a
measure of the fluorescence intensity from an individual lesions.
Measurements on a sheet of white plastic were used as a reference to
correct the fluorescence measurements of BCC for any changes in
the output of the excitation light source or the sensitivity of the
detection system. Autofluorescence was measured before each ALA
application and was subtracted from the PpIX fluorescence intensity
acquired before and after each illumination.
Response and FU
We defined CR as the absence of clinical visual basal cell
carcinoma. All patients treated in our department are seen for FU
according to the national dermatological guidelines of the Nether-
lands (NVDV). In the first year after treatment, FU was performed
four times a year, thereafter twice yearly. Patients with a propensity
of developing numerous skin lesions were seen more frequently
in an individualized scheme. FU ends 5 years past the last treated
basal cell carcinoma. Some of the patients are referred to us by
peripheral primary dermatologists and are treated as secondary
dermatological care patients and then referred back to their
primary dermatologist for further FU. We only considered FU
performed by our staff members and residents within our University
hospital. A minimal FU of 12 months is necessary for inclusion
in the study. In the single illumination group, FU varied from 12 to
41 months, mean 21 months. In the 2-fold illumination group, FU
varied between 12 and 32 months, mean 17 months. Lesions that did
not respond to therapy or recurred in the first 12 months after
treatment were included in the data analysis as in CR or recurrence.
Cosmetic outcome was not the primary goal of the study, but
remarks of patients and dermatologist were asked for and noted. The
patient and dermatologist judged cosmetic outcome to be either
good, fair, or poor.
Table 3. High-risk patients
75 J cm2 20+80 J cm2
Patient group Patients Lesions Patients Lesions
Immune compromised1 7 7 2 6
Previous radiotherapy 8 33 5 20
Goltz Gorlin syndrome 5 46 4 17
High sun exposure2 2 16 2 28
Topical arsenic use — — 1 9
1Immune compromised: HIV positive, organ recipient, or using immuno-
suppressive drugs.
2Patients who have lived more than 15 years in tropical countries and had
Fitzpatrick skin type 1.
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Statistical analysis
Kaplan–Meier analysis was performed on relative CR rates after
therapy and the log-rank test was used to compare the significance of
differences between treatment groups. The primary and overall
response rates of lesions treated with different illumination schemes
were compared using Fisher’s exact test. Differences in fluorescence
intensity were compared using Student’s t-test. Po0.05 was
considered statistically significant.
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